Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Investing.com – Oppenheimer hat die Einstufung "Outperform" und das Kursziel von 205,00 US-Dollar für die Aktie von Biogen (NASDAQ: BIIB) nach der Veröffentlichung der Finanzergebnisse für das zweite ...

Discover key insights from Biogen's Q2 2025 earnings call: strong product launches, pipeline advancements, raised EPS guidance, and resilient MS ...

Biogen Inc. (NASDAQ: BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina ...

Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate ...

By Colin Kellaher Biogen said a key European regulatory committee has recommended approval of its Zurzuvae treatment for women with postpartum depression.

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules.

AstraZeneca has unveiled a plan to invest $50 billion in the U.S. by 2030, including a multi-billion dollar manufacturing facility in Virginia.